Ionis Pharmaceuticals Announces Executive Advisory and Leadership Changes
Company Announcements

Ionis Pharmaceuticals Announces Executive Advisory and Leadership Changes

Ionis Pharmaceuticals (IONS) has provided an update.

Ionis Pharmaceuticals has engaged Onaiza Cadoret-Manier under an advisory services agreement after her departure as an executive to pursue new opportunities. Starting March 15, 2024, Cadoret-Manier will advise the company, earning $12,500 monthly until September 30, and $6,250 thereafter until the agreement concludes on January 10, 2025. Meanwhile, Kyle Jenné rejoins Ionis as executive vice president, tasked with leading the company’s commercialization efforts. Ionis appreciates Cadoret-Manier’s pivotal role in developing its commercial organization during its transition into an integrated biopharmaceutical entity.

See more data about IONS stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyIonis Pharmaceuticals price target lowered to $77 from $82 at Wells Fargo
TipRanks Auto-Generated NewsdeskIonis Pharmaceuticals Reports Q3 2024 Financial Results
TheFlyMorning Movers: CVS Health surges and ODP sinks following Q3 results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App